HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
FRIDAY, March 29, 2019 (HealthDay News) -- Recommendations have been developed for the use of genetic testing in psychiatric care, according to a statement published by the International Society of Psychiatric Genetics (ISPG).
Francis J. McMahon, M.D., from the National Institutes of Health, and colleagues reviewed the available evidence and provided guidance related to the value of clinical genetic testing in psychiatry.
The authors note that common genetic variants alone are not sufficient to cause psychiatric disorders, including depression, bipolar disorder, substance dependence, or schizophrenia. An overall risk score can be produced by combining genotypes from large numbers of common variants, but the clinical value is unclear. Growing evidence indicates that pathogenic variants with large effects on brain function play a causative role in a significant minority of individuals with psychiatric disorders. Identification of known pathogenic variants may help diagnose rare conditions. Diagnostic or genome-wide genetic testing should include counseling by a professional with expertise in mental health and genetic test interpretation. The possibility of incidental findings should be communicated whenever genome-wide testing is performed. Education programs and curricula should be developed and disseminated to enhance knowledge of genetic medicine among trainees and mental health professionals. Research efforts should be promoted to identify relevant genes and clarify the role of genetic testing and its use in psychiatric care.
"The fact that the committee could not reach consensus on every aspect speaks to the complexity of the issues," Thomas G. Schulze, M.D., president of the ISPG, said in a statement.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on May 27, 2022